High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content.
Catherine B MeadorMarina S D MilanEmmy Y HuMark M AwadMichael S RabinCloud P PaweletzRyan HartmaierGianluca LausGeoffrey R OxnardPublished in: JCO precision oncology (2021)
Plasma cfDNA genotyping is highly sensitive when adequate tumor DNA content is present. The likelihood of a false-negative cfDNA genotyping result is low in a sample with evidence of > 1% tumor content. Bioinformatic approaches are needed to further optimize the assessment of cfDNA tumor content in plasma genotyping assays.